Lv57
1320 积分 2026-04-22 加入
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2天前
已完结
P1089 Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis
3天前
已完结
Controversies in Venous Thromboembolism Risk Assessment in Inflammatory Bowel Disease: A Narrative Review
3天前
已完结
P1089 Efficacy and safety of mirikizumab as induction and maintenance treatment in adults 60 years or older with moderately to severely active ulcerative colitis
3天前
已关闭
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study
5天前
已完结
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
5天前
已完结
S1094 Comparing the Risk of Venous Thromboembolism and Pulmonary Embolism in Inflammatory Bowel Disease Patients Treated With Different Biologics: A Propensity Score-Matched, Retrospective Cohort Study
1个月前
已关闭
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
1个月前
已完结
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)
1个月前
已完结
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
1个月前
已完结
皖公网安备34019202002308
